Vanguard Global Advisers
HRMY icon

Vanguard Global Advisers’s Harmony Biosciences HRMY Stock Holding History

Vanguard Global Advisers’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.28M Buy
35,141
+8,908
+34% +$281K ﹤0.01% 1585
2026
Q1 		$735K Buy
+26,233
New +$860K ﹤0.01% 1819

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's HRMY Position: Q2 2026 in Review

Vanguard Global Advisers increased its Harmony Biosciences (HRMY) stake by 34% in Q2 2026, buying an estimated $281K and bringing the position to 35,141 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #1585.

Vanguard Global Advisers first reported a position in HRMY in Q1 2026 and has held it in 2 quarters since. 323 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Vanguard Global Advisers held 35,141 shares of Harmony Biosciences worth $1.28M as of Q2 2026.
  • Vanguard Global Advisers bought 8,908 Harmony Biosciences shares in Q2 2026, an estimated $281K.
  • Harmony Biosciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1585 holding.
  • Vanguard Global Advisers first reported a position in Harmony Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 323 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.